Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Journal Article (Journal Article;Review)
Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes.
Full Text
Duke Authors
Cited Authors
- Gaillard, S; Stearns, V
Published Date
- March 14, 2011
Published In
Volume / Issue
- 13 / 2
Start / End Page
- 205 -
PubMed ID
- 21457526
Pubmed Central ID
- 21457526
Electronic International Standard Serial Number (EISSN)
- 1465-542X
Digital Object Identifier (DOI)
- 10.1186/bcr2818
Language
- eng
Conference Location
- England